Resolving Lingering Problems or Continued Support for Pseudoscience? The ICER Value Assessment Update by Langley, Paul C.
Volume 8 | Number 4 Article 7
12-1-2017
Resolving Lingering Problems or Continued
Support for Pseudoscience? The ICER Value
Assessment Update
Paul C. Langley
University of Minnesota, langley@maimonresearch.com
Follow this and additional works at: https://pubs.lib.umn.edu/innovations
INNOVATIONS in pharmacy is published by the University of Minnesota Libraries Publishing.
Recommended Citation
Langley PC. Resolving Lingering Problems or Continued Support for Pseudoscience? The ICER Value Assessment Update. Inov
Pharm. 2017;8(4): Article 7. https://pubs.lib.umn.edu/innovations/vol8/iss4/7
Commentary FORMULARY EVALUATIONS 
 
http://z.umn.edu/INNOVATIONS                           2017, Vol. 8, No. 4, Article 7                       INNOVATIONS in pharmacy   1 
 
Resolving Lingering Problems or Continued Support for Pseudoscience? The ICER Value 
Assessment Update 
Paul C Langley, PhD 
Adjunct Professor, College of Pharmacy, University of Minnesota 
 
Abstract 
The Institute for Clinical and Economic Review (ICER) released its updated value assessment framework in mid-2017. This included 
refinements to its conceptual structure and modifications to methods of collecting and assessing evidence. Consequent to this release, 
a number of authors have commented on the updated value framework, addressing the question of whether the latest framework 
represents a major revision or merely attempts to resolve lingering problems. The purpose of this commentary is twofold: (i) to revisit 
what are considered to be fundamental flaws in the ICER value assessment framework and (ii) to question whether or not post-release 
critiques of the value framework address the fundamental weaknesses in the ICER approach: the absence of credible, evaluable and 
replicable claims for the benefits and harms of a therapy intervention. The commentary argues that while ICER sees the purpose of its 
value assessment framework as forming ‘the backbone of rigorous, transparent evidence reports’ in placing ‘scientific methods of 
evidence analysis at the heart of a clearer and more transparent process’ it falls far short of these ideals. Rather, in attempting to 
replicate in the US health care environment the evaluation framework mandated by the National Institute for Health and Care 
Excellence (NICE) in the UK, the ICER falls into the trap of generating value claims for product impact that fail to meet the standards of 
normal science.  
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Introduction 
Over the past 18 months a number of commentaries have 
been published in INNOVATIONS in pharmacy pointing to the 
absence of standards that meet the those of normal science 
for cost-effectiveness and budget impact claims 1 2.  This 
criticism applies both for pharmaceutical products and 
devices. Modeled claims for product outcomes are presented 
that: (i) lack credibility, (ii) are not evaluable and (iii) are not 
replicable. Professional associations such as the Academy of 
Managed Care Pharmacy (AMCP) and the International Society 
for Pharmacoeconomics and Outcomes Research (ISPOR), a 
large number of single payer health system agencies and 
editors of leading health technology assessment journals, 
actively encourage and set standards for the construction of 
imaginary worlds to support claims for cost-effectiveness 3 4. 
This health technology assessment ‘meme’ is well entrenched. 
Over the past 30 years, we have seen the publication of literally 
thousands of cost-effectiveness  
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modeled claims and health care decisions for formulary access 
and pricing based on these standards, which have little if any 
right to be taken seriously. Constructed as imaginary worlds, 
focusing on lifetime cost-per quality adjusted (QALY) 
simulations, we have no idea whether the claims are right, 
whether they are wrong and, in the case of the ever popular 
lifetime cost-per-QALY model, we will never know. As detailed 
in these commentaries, judged against the standards of 
normal science, lifetime cost-per-QALY models that follow 
ISPOR recommendations for ‘good research practice’, that 
embrace the National Institute for Health and Care Excellence 
(NICE) reference case, are best seen as pseudoscience.  
 
The recently released Institute for Clinical and Economic 
Review (ICER) updated value assessment framework falls 
squarely within this technology assessment tradition 5. Claims 
for cost-effectiveness and pricing are generated by modeled 
frameworks that fail to meet the standards of normal science. 
They fail the standard for claims to be credible, evaluable and 
replicable. Unfortunately, while a number of authors have 
presented critiques of the updated ICER value framework, the 
criticisms presented fail to address the limitations implicit in 
ICER’s adoption of a flawed modeling methodology. 
 
This is not the first time that the commentaries in 
INNOVATIONS in pharmacy have addressed the limitations of 
the ICER value assessment framework. Four commentaries 
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have been published on ICER reports:  heart failure (Entresto), 
multiple sclerosis, rheumatoid arthritis and cholesterol 
reduction (PCSK9 inhibitors) 6  7 8 9. Judged by the number of 
PDF downloads recorded by the University of Minnesota 
library system, these commentaries have been popular. To 
date, out of 2,481 PDF downloads for the 28 commentaries 
published to date (18 November 2017), some 619 (25%) have 
been for the four ICER reports. The ICER heart failure review 
has been the most popular with 329 PDF downloads. 
 
The purpose of the present commentary is to revisit the ICER 
value assessment framework, to include the recent Neumann 
and Cohen critique of the updated value assessment 
framework and its claim for legitimacy as the leading standard 
for drug value evaluation. 10. Although the ICER might be seen 
as a force to be reckoned with in health technology 
assessment, triggering alarm bells in the C-suites of 
pharmaceutical companies, as Neumann and Cohen put it, this 
commentary puts the case that this alarm is misplaced. 
Certainly, manufacturers should be held accountable for 
claims made for their products. However, seen from the 
perspective of the standards of normal science rather than 
from the standards of health technology assessment models 
and simulations, the ICER assessment framework should be 
put to one side. It may continue to interest those committed 
to the construction of non-evaluable claims generated by 
lifetime cost-per-quality adjusted life year (QALY) models. 
Unfortunately, we have no idea, and will never have any idea, 
as to whether the claims made are right or if they are wrong. 
Even if these modeled claims are justified as being ‘for 
information only’, formulary committees would be well 
advised to reject model based recommendations, relying 
instead of a technology assessment methodology that 
generates credible, evaluable and replicable claims for product 
acceptance, placement and pricing. 
 
ICER Critiques 
Critiques of the ICER value assessment process can be usefully 
categorized as (i) those that accept the underlying lifetime 
simulation methodology as the gold-standard for health 
technology assessment and formulary decisions as opposed to, 
as in the present case (ii) those who reject lifetime simulations 
and the construction of imaginary worlds in accepting only 
those claims for competing products which meet the 
standards of normal science for hypothesis testing and 
falsification. 
 
It is important to keep in mind that Neumann and Cohen are 
committed along with ICER to a core health technology 
assessment methodology. This puts center stage the 
construction of lifetime modeled simulations as the basis for 
comparative product evaluation; a shared commitment to the 
construction of imaginary worlds. This is see in their 
endorsement of refinements proposed by ICER: (i) presenting 
budget impact claims based on a range of product uptake 
assumptions; (ii) using net drug prices rather than list prices; 
(iii) increased scrutiny of heterogeneity of treatment effects; 
(iv) additional measures of clinical benefit; (v) applying lower 
health utilities for individuals with chronic, severe conditions; 
and (vi) paying more attention to patient context (e.g., severity 
of a condition, care giver burden). 
 
Even so, there are lingering concerns. The most prominent of 
these for Neumann and Cohen is the retention of the threshold 
budget impact calculation that allows a ceiling expenditure of 
$915 million per annum going forward. If this is exceeded in 
the ICER model calculation then the ‘short-term affordability’ 
price should be reduced to compensate. Their objections are 
not to a budget cap per se, but to the methodology employed. 
ICER should not be assessing how much payers should spend 
on a drug; that is the payer’s prerogative. Rather, ICER should 
focus on estimating and disseminating net budget impact 
forecasts of the impact of new drugs under a range of price, 
uptake and horizon assumptions.  
 
The second lingering problem is the narrow healthcare 
perspective taken in the ICER base-case cost-effectiveness 
case. While this may appeal to payer audiences, ICER should 
put alongside this a comprehensive societal impact model. 
This, presumably, would take a lifetime horizon and, once 
again, generate non-evaluable claims, this time for the societal 
impact.  
 
The final lingering concern is with the use of cost-effectiveness 
thresholds. However, it is not the value of the threshold that is 
the problem, it is the introduction of thresholds into the ICER 
value assessment in the first place. ICER seems to see itself 
(mistakenly to the reviewer’s minds) as the self-appointed 
decision maker and not, more appropriately, as an evaluation 
agency or consultant. It is not ICER’s role, unlike the role of 
NICE in the single payer UK health system, to determine what 
tradeoffs payers and patients should be willing to make. 
 
Whether these ‘lingering concerns’ will have any substantive 
impact on how ICER presents its results and recommendations 
is a moot point. After all, the terminology itself suggests that 
these issues are not that important and probably can be 
resolved by a more extended presentation of modeled 
scenarios. A more substantive ‘lingering concern’ might be 
whether the claims ICER value assessment framework is of any 
interest to health care decision makers? After all, as Neumann 
and Cohen conclude: 
 
An inherent flaw is that ICER is striving to 
provide a public good in a fractured US 
healthcare market, where its private payer 
audiences have short time horizons and 
practical constraints that often do not align 
with societal value.  
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If this is the case then the more pertinent argument, which 
goes to the acceptance of what is seen here as a flawed 
technology assessment methodology, is whether heath care 
decision makers are even interested in the ICER value 
assessment framework. In the wider societal context, whether 
the construction of imaginary worlds, which the authors 
accept uncritically, is the gold standard for cost-effectiveness 
claims? 
 
Note should also be taken of the comments offered by the 
National Pharmaceutical Council (NPC) on the updated value 
assessment framework. Again, the NPC accepts the underlying 
technology assessment methodology11.  Continuing concerns 
are: (i) the need to provide transparency through full access to 
the model so that results can be reproduced and tested; (ii) the 
continued use of the $50,000 cost-per-QALTY threshold in 
voting on ICER recommendations; and (iii) the need to 
eliminate affordability assessments. At the same time the ICER 
is complimented on its intention to include a ‘cost per 
consequence’ measure in its reports.  
 
NPC concerns are also voiced in their recent comments on a 
proposed (announced) collaboration between the ICER and 
the Veterans Administration (VA) 12. Issues raised include: (i) 
the need to broaden the evidence base for value assessments 
beyond RCTs in post-product approval analysis and research in 
the ‘unique’ VA population; (ii)  accommodating the 
perspective of veterans and their families in complex 
conditions such as post-traumatic stress disorder (PTSD), loss 
of limbs, chronic pain and return to work; (iii) capturing a wider 
set of value inputs and not link benefits to as single value 
assessment; and (iv) avoid imposing arbitrary spending limits 
on drugs. 
 
Credibility, Evaluation and Replication 
Unless health care decision makers and, it must be added, 
pharmaceutical and device manufacturers are prepared to put 
to one side the currently accepted heath technology 
assessment commitment to base cost-effectiveness claims on 
imaginary lifetime constructs, then groups such as ICER will 
continue to flourish. ICER’s access to resources, its effective 
management, its acceptance by key players and its 
independent status, will ensure its continued dominance of 
the health technology assessment space. This should not be 
taken as a criticism of ICER in its efforts to influence formulary 
recommendations, placement and pricing. Rather, it is a 
criticism directed at ICER’s acceptance of a flawed technology 
assessment ‘meme’ that puts to one side the standards of 
normal science. If ICER was prepared to focus on claims that 
were credible, evaluable and replicable then its efforts could 
be supported. The question is, of course, whether ICER (and 
groups such as ISPOR and the AMCP) would be prepared to 
abandon their present position. 
 
For those who have followed the commentaries published in 
INNOVATIONS in pharmacy over the past 18 months, the 
limitations of the current health technology assessment 
‘meme’ should be well known. For present purposes, as the 
focus is again on the ICER value assessment framework it is 
worth restating the key arguments. These can be considered 
under the following heads: 
 
• Standards of normal science 
• Replication and clinical claims 
• Claim timeframe 
• Willingness-to-pay-thresholds 
• Constructing QALYS 
• Adherence and persistence 
• Pricing and costs 
• Potential confounding factors 
• Access to the ICER model 
• Immunity to feedback 
Standards of Normal Science 
The standards of normal science, as they should apply in health 
technology assessment, are aptly summarized by the motto of 
the Royal Society (founded 1660; Royal Charter 1662): Nullius 
in verba (take no man’s word for it). If a modeled cost-
effectiveness claim is to meet these standards then it has to: 
(i) involve the construction of an empirically evaluable, 
coherent theory and (ii) facilitate the testing of hypotheses 
through experimentation of observation. A theory is not to be 
judged by the realism of its assumptions. To argue that a 
lifetime cost-per-QALY based claim is to be accepted as an 
input to formulary decision making on the grounds that the 
simulation is ‘realistic’ is unacceptable. Not only is it impossible 
to claim that a simulation projecting forward 20 or 30 years is 
realistic but, as detailed below, health technology assessment 
standards in respect of pricing and compliance, ensure that it 
is not intended to be ‘realistic’. Should the claim be that a 
model is realistic, but not too realistic? Perhaps ICER could 
collaborate with ISPOR to construct a ‘lifetime model realism’ 
scale to rank models where a multiattribute weighting yields a 
score on a range from 0 = not realistic to 1 = completely 
realistic? 
 
The standards for hypothesis testing through experimentation 
and observation have been in place since the 17th century 13. 
They demarcate science from pseudoscience or, as more 
strongly stated by Pigliucci, they demarcate natural selection 
from intelligent design 14 .  Failure to accept and meet the 
standards for experimentation and observation, the core 
feature of health technology assessment models such as those 
central to the ICER value assessment framework, effectively 
put claims made outside the realm of normal science. This 
criticism applies equally to the ICER as well as single payer 
agencies such as NICE in the UK, the PBAC in Australia and 
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PHARMAC in New Zealand. Of course, the fact that NICE 
embraces the reference standard of constructing imaginary 
worlds does not mean that others should follow. 
 
It is worth noting that this rejection of the standards of normal 
science in health technology assessment is recognized and 
endorsed by practitioners. The position taken in the Canadian 
health technology guidelines, for example, is quite explicit: 
Economic evaluations are designed to inform decisions. As such 
they are distinct from conventional research activities, which 
are designed to test hypotheses 15. Taken a face value, 
therefore, health technology assessments in ‘informing’ 
decisions on products and devices are not concerned with the 
benefits and harms that might be evaluated in treatment 
practice, or on the belief or otherwise in the claims from 
randomized clinical trials (RCTs) and whether they can be 
replicated, but in the construction of simulations (imaginary 
worlds) which are designed to generate non-evaluable claims. 
In respect of this last point, it should come as no surprise that 
the Canadian Agency for Drugs and Technologies in Health 
(CADTH) embraces lifetime cost-per-quality adjusted life year 
(QALY) models as the gold standard 16.   
 
Replication and Clinical Claims 
A feature that the ICER has in common with single payer 
assessment agencies and, in the US, formulary committees, is 
the willingness to take clinical claims from Phase 2/3 
randomized clinical trials (RCTs) at face value. Rather than 
taking a critical perspective on the validity of these claims and 
the extent to which the claims have been replicated, the 
analysis typically proceeds to an indirect modeling comparison 
to rank competing products in disease and therapy areas from 
a limited evidence base, driven by modeled indirect 
comparisons. It is always important to remember that indirect 
comparisons and the ranking of interventions are only ‘as 
good’ as the technique employed; the question of claims 
replication is the critical issue.  
 
Clinical claims from pivotal RCTs are typically the primary input 
to indirect product comparisons. Given that these claims are 
then extrapolated over the lifetime of the patient in the value 
assessment simulation, it seems odd that ICER puts to one side 
any attempt to validate these clinical claims or to suggest how 
these claims might be validated either through head-to-head 
RCT comparisons or, more to the point, an assessment of these 
claims in clinical practice. This neglect stands in contrast to the 
standards proposed in the Minnesota formulary submission 
guidelines 17 18. In the Minnesota guidelines manufacturers are 
asked to submit, as part of their product dossier, a protocol 
detailing how the claims made are to be evaluated in 
treatment practice with the results reported back to the 
assessment formulary committee. Feedback, as detailed 
below, is seen as a critical element in formulary acceptance, 
placement and pricing. Manufacturers are not asked to put 
forward lifetime simulations to support non-evaluable 
incremental cost-outcomes claims. Rather, the focus is on 
clinical and cost-outcomes claims that are credible, evaluable 
and replicable. 
 
It is worth noting that the requirement for credible claims and 
a protocol to support those claims is not new. This approach 
was proposed over 12 years ago in the development of draft 
guidelines to support formulary committee evaluations of new 
products as well as disease area and therapeutic class reviews 
in the WellPoint (now Anthem) health system outcomes based 
formulary 19 20.   
 
Claim Timeframe 
The position taken by ICER, and one, as noted above, that is 
entirely consistent with standards advocated by the AMCP, 
ISPOR and agencies such as NICE, is that ‘the grounding of any 
evaluation of value should recognize the long-term 
perspective on both outcomes for patients and costs’. This is 
achieved by simulations that ‘estimate outcomes and costs at 
the longest feasible time horizon, usually the full lifetime of 
patients’. In practical terms this means, presumably, that 
claims for incremental cost-effectiveness are appropriately 
based on simulations, driven by selected assumptions, which 
can extend over 20, 30 or even more years. Simulated benefits 
which might only be realized over many years are thus a ‘core’ 
element in the value framework.  
 
Claims based on these simulations, together with the 
discounting of the simulated stream of benefits and costs, are 
clearly not intended to be evaluable. Indeed, given the 
inevitable entry of new products within this timeframe, long-
term benefits and harms would presumably accrue to the 
succession of new products, given patient switching behavior, 
and not to the present product configuration which is, by 
assumption, to remain unchanged with patient’s adherent to 
this product over their lifetimes. At the same time, within this 
modeling framework considerable attention is given to 
justifying and the construction of health states through which 
the modeled target population are assumed to progress. This 
is supported by ISPOR with a range of publications detailing 
what they see as professional standards for constructing 
imaginary worlds, together with imaginary world workshops 
presented regularly at their various global conferences 21 22 23. 
This level of commitment and reinforcement has guaranteed 
that the health technology assessment framework is well 
entrenched. Or, to put it in the language of memes and 
memeplexes, the role of ISPOR and other technology 
assessment agencies as high fidelity replicators 24  
 
 
Willingness-to-Pay Thresholds 
Although it would be unfair to characterize published models 
that claim cost-effectiveness for their sponsor’s product as 
nothing more than marketing exercises, it is intriguing that all 
too often the model generates claims that fall within a 
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willingness-to-pay threshold, and as such the product is 
claimed to be cost-effective. This has been well documented 
in commentaries in the INNOVATIONS in pharmacy  that have 
reviewed cost-effectiveness studies published in Value in 
Health, PharmacoEconomics and the Journal of Medical 
Economics 25 26 27. 
 
It is also instructive to review for individual products the NICE 
assessment process in the UK where a manufacturer, given the 
mandatory reference case guidelines for constructing 
imaginary worlds,  submits a modeled claim that is then passed 
on to a review group who proceed to dissect, restructure and 
present their version of the modeled imaginary world. This is 
further evaluated by NICE and, eventually, an agreed future 
world is presented. Willingness-to-pay thresholds (usually 
£20,000 per quality adjusted life year) are applied and, with 
some exceptions, NICE approval of the product. The ICER 
follows a similar process (NICE-lite) with the exception being 
that while the model may be constructed by an academic 
group under contract to ICER, the value assessment model is 
not put out for independent review. There is certainly a public 
comment phase following the ICER draft report, but given the 
time frame involved there is little scope for those comments 
from stakeholders to be taken on board. The key issue is the 
absence of a well-documented independent review of the ICER 
value assessment reporting in the public domain. This, of 
course, assumes that the participants are in agreement on the 
contribution of constructing imaginary worlds. 
 
Assuming a specific QALY measure is mandated (in the case of 
NICE the EQ-5D) with the single payer’s agency also mandating 
willingness-to-pay thresholds, then the there is no debate over 
whether or not the product, by definition, is cost-effective. 
This is not, as Neumann and Cohen point out, the case with 
ICER as it is not the agent of the various US health payers who 
have, let us assume, agreed on modeled willingness-to-pay 
thresholds. Assuming, further, that willingness-to-pay is 
relevant to decision making in the US, they cannot claim a 
product is cost-effective (with recommendations for price 
discounting) unless the decision maker concurs with (i) the 
application of the specific ICER lifetime cost-per-QALY model 
as one among many modeled options; (ii) the application of an 
agreed QALY measure; and (iii) the relevance of the ICER 
willingness-to-pay threshold (or thresholds). At best, as 
Neumann and Cohen point out, ICER is an evaluator not a self-
appointed decision maker. 
 
Unfortunately, in the case of NICE, moving from the early EQ-
5D-3L to the later EQ-5D-5L version of the instrument a slight 
problem has arisen which rather undercuts the claim for a 
robust and invariant QALY measures as a reference case. A 
recent report by Wailoo et al of the Decision Support Unit at 
the University of Sheffield compared response distributions 
between the 3 level and 5 level versions of the instrument in 
an assessment of the ability to map between the two measures 
28. The report found significant statistical differences in the 
covariates and latent factors between most dimensions of the 
two instruments and, as a result, moving from three levels to 
five levels ‘is just not just a uniform realignment’. As a result, 
the two versions of the instrument ‘produce substantially 
different estimates of cost-effectiveness’.  While it is possible 
to map between the two instruments, this may be at the 
expense of claims for the instrument as a generic measure, 
with Wailoo et al pointing out that mapping may be only 
appropriate within disease areas. At the same time, as noted 
in previous commentaries, there are recent claims that the 
preferences expressed over hypothetical health states are 
inconsistent with the assumptions of the multiattribute utility 
theory that underpins measures such as the EQ-5D 29.  
 
The fact that the US is a diverse (‘fractured’) health care system 
with multiple decision makers, makes any broad claim for cost-
effectiveness in the US impossible. A situation that is made 
more complex (if not absurd) by the fact that individual 
decision makers would have had no input whatsoever into the 
ICER model framework, even to the extent of denying the 
relevance of a lifetime cost-per-QALY model and thresholds as 
cutoffs.  A situation that remains unchanged with proposed 
supplementary cost-per-outcome measures. What is the 
threshold value for cost-per-event avoided? Can diverse health 
systems agree on a model framework that supports lifetime 
cost-per-outcome claims?  Finally, it should be noted that 
under the Patient Care and Affordable Care Act (ACA), the 
Patient Centered Outcomes Research Institute (PCORI) that 
cost-per-QALY or similar measures cannot be used ‘to 
determine coverage, reimbursement, or incentive programs 
under Title XVIII’ 30. 
 
The US is not, however, alone in putting cost-per-QALY claims 
to one side. While the ICER defends its position by pointing out 
that this standard has been accepted by many academics, 
manufacturers and patient groups, it should be pointed out 
that the acceptance is not universal. Germany, for example, is 
not interested in QALYs and they have been rejected by the 
Spanish Ministry of Health 31  32. In New Zealand, while cost-
per-QALY claims are accepted, the Pharmaceutical 
Management Agency (PHARMAC) has rejected the application 
of thresholds. The argument is that given the range of criteria 
that contribute to formulary decisions and the requirement in 
New Zealand that pharmaceuticals are kept within a fixed 
budget, thresholds are inappropriate33. As budgets vary from 
year-to-year, there is no threshold below which a 
pharmaceutical is considered cost-effective. 
 
There is the real possibility that technology assessment 
decisions may have to abandon cost-per-QALY assessments as 
the universal gold standard for resource allocation and 
formulary assessment in favor of more disaggregated, disease 
specific measures. Even if ICER continues to argue for a cost-
per-QALY value assessment, there are concerns that in 
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constructing incremental cost-per-QALY simulations with 
QALY measures that are taken from the literature, the 
measures captured in the simulation may not be compatible 
across the products assessed or for comparisons between ICER 
reports for different products in a range of disease areas. 
Threshold cost-per-QALY claims are only relevant, assuming 
that the QALY threshold is accepted, if resources are allocated 
across disease areas utilizing a common QALY instrument. ICER 
should commit, presumably, to a common QALY measure used 
across all its value assessments. 
 
It is worth noting that the ICER updated value assessment 
rejects multicriteria decision analysis (MCDA) because it does 
not believe ‘that the methods for weighting individual 
elements are robust enough’ to ensure the reliability  of value 
judgements . It has found the technique ‘too complicated for 
reliable use’. A criticism that might equally well apply to its 
modeling for value assessment thresholds and budget impacts. 
 
Constructing QALYS 
It is possibly surprising that, given the lack of interest in the US 
and the outright bar on the application of cost-per-QALY based 
claims and thresholds under the ACA that the ICER perseveres 
with a value assessment framework that has, as its centerpiece 
for pricing recommendations, cost-per-QALY thresholds 
generated by imaginary worlds. Given this, it is important also 
to note that the QALY measures utilized in lifetime cost-per-
QALY claims are often cobbled together from the literature. 
Literature sources are culled for utility measures, covering 
both generic and disease specific measures in an attempt to 
generate ‘acceptable’ measures to capture the health states of 
the constructed target population as it progresses over its 
lifetime health state experiences. Heath states which, in turn, 
are literature based constructs. This practice is defended and 
any criticisms are deflected by the model builder arguing for 
input parameter distributions and various sensitivity analyses 
to support claims expressed in probabilistic terms.  
 
Adopting the QALY as the outcome gold standard, of course, 
effectively precludes any empirical evaluation of clams made 
for competing products. In the US (and in other jurisdictions) 
QALYs are not regularly generated as part of patient electronic 
medical records (EMRs) or as part of administrative data sets 
whether these are from physician practices or hospital 
records. Indeed, even if there was an effort to collect QALY 
measures, there would be the further question of which QALY 
measure, generic or disease specific, to collect. A situation that 
is made even more absurd by the difficulty of crosswalking one 
QALY measure to another. As noted, it seems as if the intent 
of those advocating standards for health technology 
assessment have gone out of their way to ensure that claims 
made, with the lifetime cost-per-QALY ( NICE reference case) 
paradigm are impossible to evaluate 34.  
 
Adherence and Persistence 
A question that ICER needs to address in each of its modeled 
lifetime value assessments is compliance with therapy. There 
is now abundant evidence that few patients are either 
adherent to or persistent with therapy in the long-term; that 
is, beyond two or three years. If this is the case, as pointed out 
some time ago in the commentary on the ICER heart failure 
analysis, if patients are not persistent with therapy why do 
simulations continue to assume compliance over the lifetime 
of the patient? This neglect is also puzzling given the attention 
to product uptake assumptions proposed by the ICER is this 
revised value assessment. This is not always the case. ICER in 
its recent value assessment of the VMAT2 inhibitors includes 
discontinuation of therapy in modeling tardive dyskinesia35 . 
However, this appears to be the exception rather than the rule. 
The obvious question is why this is not introduced across the 
board. 
 
It is certainly possible to introduce assumptions regarding 
adherence and persistence with therapy into lifetime 
simulation models. Whether it is worth the while is debatable. 
A more useful approach, if the focus is on a commitment to 
generating evaluable claims, would be to focus on the short 
term. With access to an ICER model it would be entirely 
possible to reformulate the model to accommodate 
compliance behavior. This, from ICER’s perspective would be 
risky as it could change completely claims for incremental cost-
effectiveness to those based on short term QALY outcomes 
(assuming that QALYs measured over a short time horizon are 
meaningful). If, for example, the claim made is that the 
benefits to patients only accrue in the long term to the 
minority who are compliant with therapy over this timeframe 
then any long-term incremental cost-effectiveness claim 
would be qualified by outcomes for those patients who 
dropped out from therapy. This situation would be made more 
complex if assumptions were made as to differential 
compliance behavior across products in the therapeutic area. 
Perhaps ICER could consider as a standard element of their 
value assessment evaluable modeled claims for each of the 
first 3 years following index prescription.  
 
Pricing and Costs 
The ICER modeling of cost-effectiveness ‘will not routinely 
make estimates of price changes across comparator 
treatments linked to patent and exclusivity time horizons’. As 
pointed out in the ICER commentaries in INNOVATIONS in 
Pharmacy, to assume the absence of pricing changes in 
pharmaceuticals (and other medical resource inputs) is rather 
odd given the evidence for manufacturer’s pricing policies to 
regularly increase unit price, often far in excess of any medical 
price inflation index. ICER’s defense is that ‘assumptions about 
price changes are not currently the standard in health 
technology assessment agency cost-effectiveness analyses ‘ as 
it is ‘very difficult to predict the pricing landscape many years 
into the future …’. There is no disagreement with that point 
although it might be added that (i) if price increases are built 
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into the imaginary world(s) scenario, there is no reason to 
assume there will be a consistent pricing policy across products 
in a disease or therapy area and (ii) pricing decisions may 
respond to ICER recommendations for discounting. A more 
believable response might be: if this is the case, why not admit 
the virtual impossibility of long-term simulations that might 
conceivable bear any relation to a possible future reality and 
focus, as recommended here, on short-term credible claims 
with feedback to decision makers? After all, if you claim that 
your lifetime simulation should be realistic why put to one side 
pricing assumptions which are, on the evidence for past pricing 
behavior, an integral part of any cost-effectiveness simulation? 
 
Potential Confounding Factors 
Again, there is now ample evidence that the response to 
therapy within a target patient population depends on a range 
of potential confounding factors. These may include 
comorbidities such as diabetes and cardiovascular disease in 
older populations, the presence of depression, anxiety, sleep 
disorders and pain, as well as access to care and employment 
status. While ICER may consider these as ‘contextual 
considerations’ which may be put to one side consequent to a 
vote by ‘stakeholders’ as to their potential benefits and 
disadvantages, the concern is that the modeling framework is 
ever further distanced from any claims for realism in its future 
scenario-driven reality. 
 
Creating lifetime simulation models that deliberate exclude 
factors such as compliance, pricing and costs and a range of 
other confounding factors must raise doubts again as to 
whether or not the commitment to a lifetime technology 
assessment ‘meme’ is a worthwhile endeavor. The defense 
that ‘this is what everyone does’ is not acceptable. It puts to 
one side any notion of progress in health care decision making 
in favor of adhering to and attempting to further refine what 
might be considered a bankrupt methodology. One is 
reminded of the question of why a driver who has lost his car 
keys at night only looks in the area around the lamppost: the 
response being – “ that is where the light is”.  
 
Access to the ICER Model 
The question of whether or not access to the ICER cost-
effectiveness model might resolve issues depends on the 
underlying structure and assumptions of the model itself and 
the belief reviewers have in the merits of the lifetime model 
exercise.. If the model is designed to generate non-evaluable 
claims then, unless by dint of major restructuring, it is doubtful 
if one can translate the model into one that is capable of 
generating credible and evaluable claims. If so, then access to 
the model is clearly a waste of time. All access allows is to 
simply rearrange deckchairs. Competing claims may emerge, 
but these will still be variations on a theme: the claims are still 
non-evaluable. Presenting external reviews with access to a 
lifetime cost-per-QALY model which, within presumably limits 
set by ICER on the ability to challenge or manipulate the 
underlying structure of the model means we are still left with 
a model that fails to meet the standards of normal science.  
 
Understandably, ICER appears reluctant to release their model 
to independent assessors or to health system decision makers. 
The problem is, of course, that there can be, as demonstrated 
in the literature, a plethora of models, each sponsored by 
competing interests. Releasing the ICER model to public 
scrutiny runs the risk of encouraging competing models with 
the result that, from the payers’ perspective in a fragmented 
health system, decisions would have to be made across 
competing imaginary futures. It is entirely possible that with 
model competitions, one class of models might incorporate 
pricing projection and assumptions regarding adherence and 
persistence behavior while another class, including the ICER 
model, excludes these. A situation, it might be noted that has 
been addressed in the INNOVATIONS in pharmacy 
commentaries for lifetime simulation models in diabetes 
mellitus. Taking its cue from the Mt Hood challenge meeting in 
diabetes modeling, ICER might consider sponsoring model 
competitions in specific disease areas as a prelude to releasing 
a value assessment report 36.  
 
Immunity to Feedback 
Of course, if ICER was prepared to concede that there is a need 
to develop modeling frameworks that were capable of 
generating short-term evaluable claims that could be driven by 
a protocol that generated feedback to a formulary committee, 
then the issue of competing imaginary worlds  might be 
usefully resolved. Unfortunately, this is most unlikely to occur 
given ICER’s commitment to a NICE-lite lifetime cost-per-QALY 
methodology.  This is made quite clear in the revised value 
assessment framework which is, to make the point once again, 
only one of a potential range of competing value assessment 
frameworks that could be sponsored by other independent 
agencies.  
 
If manufacturers, pharmacy benefit managers and health care 
systems are to take ICER claims for cost-effectiveness, pricing 
and budget impact at face value, then it is presumably 
incumbent upon ICER to provide a value framework that 
generates feedback to decision makers. Unfortunately, this is 
not the case.  Indeed, the ICER value framework would appear 
to be designed to exclude effectively any feedback to decision 
makers. Decision makers are forced to either accept or reject 
the ICER lifetime modeled recommendations and their claims 
for comparative benefits and harms.  There is no mechanism 
which, as a new product or device is introduced to treatment 
practice, allows decision makers to evaluate the merits of the 
ICER claims; let alone the validity of the assumptions which are 
built into the ICER models.  While a model, as noted above 
should not be judged on the validity/reality of its assumptions, 
there are critical assumptions, notably in respect of adherence 
and persistence that if excluded cast doubt on the overall 
merit of the exercise. 
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The current ready access to internet-based reporting 
platforms to support RCT and observational studies at low cost 
and in real time provide a vehicle for feedback on evaluable 
claims in a timeframe relevant to health care decision makers, 
physicians and patients. Protocols can be implemented in 
target populations where, as detailed below, patients can 
report on-line in real time with these responses supported by 
reports from the electronic medical record (EMR). The ready 
access to these platforms gives further support to the 
development of short-term modeled claims that meet the 
standards of normal science. Hypotheses can be tested 
through experimentation and observation. There is also 
feedback to model builders who can assess the strengths and 
weaknesses of their models, setting the stage for more robust 
model frameworks. 
 
Conclusions 
Once a commitment is made in incremental cost-outcomes 
analysis to a lifetime perspective any claims made for clinical 
outcomes, cost-consequences and quality of life are, by 
definition, non-evaluable. Even if the model builder builds in 
credible claims that may be evaluated in the short-term, we 
are still in the position of not knowing whether the ICER 
lifetime recommendations are right or whether they are 
wrong; and we will never know. While this commitment to the 
construction of what are best described as imaginary worlds 
may be defended in terms that they are not meant to generate 
testable hypotheses but rather to provide ‘information’ for 
decision makers, the decision maker has no basis for either 
accepting or rejecting the claims. As far as the decision maker 
is concerned the simulation is best seen as a ‘black box’ that 
could equally well be re-engineered to generate competing 
claims. Arguments that the simulation is ‘realistic’ are simply 
not acceptable when the simulation fails to accommodate, for 
example, assumptions as to anticipated compliance and 
pricing behavior. Unfortunately, even if such assumptions 
were built into the model, the lifetime perspective adopted 
guarantees that any claims made fail to meet the standards of 
normal science. 
 
Can the ICER position be challenged? Quite clearly it can be as 
this commentary has outlined. The challenge, however, is not 
to ICER itself as it can continue to further refine its value 
assessment framework and the continued modeling of 
imaginary worlds. The challenge is to the mainstream health 
technology assessment belief in the information value of 
lifetime, cost-per-QALY imaginary worlds irrespective of 
whether these are narrowly payer focused or whether they 
attempt a wider, yet still imaginary construct, which takes a 
societal perspective. 
 
The essential point is that those taking up the challenge to this 
commitment to constructing imaginary worlds accept the 
standards of normal science: health technology assessment 
claims must be credible, evaluable and replicable in a 
timeframe that is relevant to decision makers. But who will 
mount the challenge? ISPOR and associated professional 
groups are not candidates: they have too much sunk capital in 
the ‘information vs. hypothesis testing’ technology assessment 
meme. The obvious candidates are, on the one hand, health 
care systems and their various formulary committees while, on 
the other hand, pharmaceutical and device manufacturers.  
 
From the formulary committee perspective standards have 
already been proposed in the Minnesota guidelines. Adoption 
of these guidelines by a major health system would clearly act 
as a catalyst in bringing manufacturers in line. A 
complementary scenario would be where a major 
manufacturer, possibly acting in tandem with a health system, 
announced that it was focusing its health technology 
assessment resources on developing models that, once again, 
were designed to generate credible, evaluable and replicable 
claims in a timeframe that is relevant to decision makers. 
Submissions to healthcare systems, following an unsolicited 
request for a product dossier would detail and, at the same 
time, propose how the claims could be evaluated in target 
patient populations. 
 
From a strategic perspective, the commitment by a 
manufacturer to abandoning the current, mainstream 
technology assessment ‘meme’ in favor of one that met the 
standards of normal science has few downside risks. Apart 
from objections from professional and other technology 
assessment groups, the principal beneficiaries would be 
decision makers, physicians and patients in health care 
systems. For the first time a manufacturer would commit to 
generating claims and assessment protocols that would be 
evaluated in real time, providing ongoing feedback. This 
engagement would not, of course, have to be repeated across 
clients. Given the typical rate of uptake of new products, ‘first 
adopter’ health systems could be the vehicle for claims 
assessment and feedback. These ‘first adopters’ could reflect 
the disparate nature of the US healthcare system with 
evaluations targeted to specific patient groups within systems 
such as the Veterans Administration, capturing patient 
characteristics specific to that system.  
 
The first step for a manufacturer would be to announce that it 
was investing in a technology assessment process that 
recognized the importance of generating credible and 
evaluable claims. This would be seen as a natural extension of 
its commitment to high quality RCTs that, by definition, met 
the standards of normal science. The shortcomings of the 
present standards would be detailed, pointing to the real time 
information vacuum that exists in focusing technology 
assessment activities on the construction of any number of 
competing imaginary worlds, where claims for cost-
effectiveness and pricing adjustments are not to be taken 
seriously.  
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Second, the manufacturer would have to align internal 
activities to drawing up a set of standards for short term 
modeling to support clinical, cost-effective and budget impact 
claims. Protocols for claims assessment, specific to disease and 
therapeutic area, would be agreed. These elements would be 
combined in a dossier structure to meet unsolicited requests 
from health systems. 
 
Third, standards would have to be agreed for protocol 
implementation and reporting. Given time and resource 
constraints, observational tracking studies would be the 
preferred option. The design of the tracking study, which could 
combine elements from the electronic medical record (EMR) 
as well as study specific patient questionnaires supported by 
internet-based platforms, would be detailed and agreed with 
the health system and physician practices. Finally, a 
publication strategy would be detailed, to include prior media 
release and presentations announcing the adoption of this 
evaluable claims strategy.   
 
From the perspective of meeting the standards of normal 
science in health technology assessment, it is a moot point as 
to how sustainable is the present commitment to the 
construction of lifetime cost-per-QALY models. Certainly, the 
alternative presented here is achievable. At the same time, it 
is of interest to speculate on how adoption of this commitment 
to evaluable claims would resonate outside of the US. As 
detailed in the INNOVATION in Pharmacy commentaries, many 
single payer systems have mandated lifetime cost-per-QALY 
models in product and device submissions, and where 
willingness-to-pay thresholds are in place, their impact for 
pricing and formulary acceptance. However, the ability to 
actually track evaluable modeled claims through low cost 
internet-based reporting platforms offers agencies the option 
of redrafting their guidelines to focus on evaluation, 
replication and feedback. Whether this option is taken up 
remains an open question.  
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